Document
type: Class

Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis
type: Document
type: Continuant
type: Entity
most specific type: Academic Article
type: Generically Dependent Continuant
related by: 5820080
type: Academic Article
type: Article
related by: 5820064
related by: 5820066
type: Thing
type: Information Content Entity
language: Inglese

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

individual
rights: termsOfUse
date: 2026-08-24T09:42:47
publisher: Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis
type: Document
label: RDF description of Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis - http://irises.unisr.it/resource/item/105575

Generically Dependent Continuant
type: Class

Article
type: Class

Inglese
type: Language

5820064
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis

5820066
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis

Information Content Entity
type: Class

5820080
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis